81147-92-4

Basic information

• Product Name: Esmolol
• Synonyms: ESMOLOL;4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-benzenepropanoicacimethyle;asl8052-001;methyl4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)benzenepropanoate;4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzenepropanoic acid methyl ester;Methyl 3-[4-(2-hydroxy-3-propan-2-ylamino-propoxy)phenyl]propanoate;Methyl 4-[2-hydoxy-3[(1-methylethyl)amino]-propoxy]benzenepropanoate;3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propanoic acid methyl ester
• CAS NO: 81147-92-4
• Molecular Formula: C₁₆H₂₅NO₄
• Molecular Weight: 295.37
• Mol File: 81147-92-4.mol

Chemical Properties

• Melting Point: 48-50 °C
• Boiling Point: 430.2 °C at 760 mmHg
• Flash Point: 214 °C
• Appearance: /
• Density: 1.026
• Vapor Pressure: 3.62E-08mmHg at 25°C
• PKA: 13.88±0.20(Predicted)
• Water Solubility: Slightly soluble
• Merck: 14,3700
• CAS DataBase Reference: Esmolol(CAS DataBase Reference)
• NIST Chemistry Reference: Esmolol(81147-92-4)
• EPA Substance Registry System: Esmolol(81147-92-4)

Safety Data

• RTECS: DA8345500
• Hazardous Substances Data: 81147-92-4(Hazardous Substances Data)

Usage

Originator

Esmolol,AroKor Holdings

Uses

Different sources of media describe the Uses of 81147-92-4 differently. You can refer to the following data:
1. Esmolol is a cardioselective beta1 receptor blocking agent.
2. Agricultural chemical.

Therapeutic Function

Beta-adrenergic blocker

Hazard

A reproductive hazard.

Clinical Use

Esmolol (Brevibloc) is a short-acting intravenously administered β1-selective adrenoceptor blocking agent. It does not possess membrane-stabilizing activity or sympathomimetic activity. Esmolol is used in the treatment of supraventricular tachyarrhythmias for rapid control of ventricular rate and reduction of myocardial oxygen consumption. Discontinuation of administration is followed by a rapid reversal of its pharmacological effects because of esmolol’s rapid hydrolysis by plasma esterases.

Side effects

The most frequently reported adverse effects are hypotension, nausea, dizziness, headache, and dyspnea.As with many β-blocking drugs, esmolol is contraindicated in patients with overt heart failure and those in cardiogenic shock.

Metabolism

The -blocker esmolol (Brevibloc) is unusual in that it is very rapidly metabolized; its plasma half-life is only 9 minutes. It is subject to hydrolysis by cytosolic esterases in red blood cells to yield methanol and an acid metabolite, the latter having an elimination half-life of about 4 hours. Only 2% of the administered esmolol is excreted unchanged. Because of its rapid onset and short duration of action, esmolol is used by the intravenous route for the control of ventricular arrhythmias in emergencies.

InChI:InChI=1/C16H25NO4.ClH/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3;/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3;1H

Upstream product

• 81147-94-6 methyl 3-<4-(2,3-epoxypropoxy)phenyl>propionate 
• 75-31-0 isopropylamine 
• 106-41-2 4-bromo-phenol 
• 1588490-32-7 3-(4-hydroxyphenyl)-N-(quinolin-8-yl)propanamide 
• 5597-50-2 3-(4-hydroxyphenyl)propionic acid methyl ester 
• 501-97-3 4-hydroxyphenylpropionic acid 

Downstream Products

• 1187651-71-3 N-(2-aminoethyl)-3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanamide 
• 115729-56-1 methyl (S)-3-[4-[2-Hydroxy-3-(isopropylamino)propoxy]phenyl]propanoate 
• 117405-53-5 esmolol 

Relevant articles and documents

Pd(II)-catalyzed intermolecular arylation of unactivated C(sp 3)-H bonds with aryl bromides enabled by 8-aminoquinoline auxiliary

An example of using readily available, less reactive aryl bromides as arylating reagents in the Pd(II)-catalyzed intermolecular arylation of unactivated C(sp3)-H bonds is described. This reaction was promoted by a crucial 8-aminoquinolinyl directing group and a K2CO3 base, enabling regiospecific installation of an aryl scaffold at the β-position of carboxamides. A mechanistic study by DFT calculations reveals a C(sp3)-H activation-led pathway featuring the oxidative addition as the highest energy transition state.

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

ANTIHYPERTENSIVE THERAPY

A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.

FLUORESCENCE BASED DETECTION OF SUBSTANCES

A method for the fluorescent detection of a substance, the method comprising providing particles comprising a metal or a metal oxide core, wherein one or more optionally fluorescently tagged antibodies or human specific peptide nucleic acid (PNA) oligomers for binding to a substance is/are bound, directly or indirectly, to the surface of the metal or metal oxide; contacting a substrate, which may or may not have the substance on its surface, with the particles for a time sufficient to allow the antibody/PNA oligomer to bind with the substance; removing those particles which have not bound to the substrate; if the antibodies or PNA oligomers are not fluorescently tagged, contacting the substrate with one or more fluorophores that selectively bind with the antibody and/or substance, then optionally washing the substrate to remove unbound fluorophores; and illuminating the substrate with appropriate radiation to show the fluorophores on the substrate.

Method for treating resistant hypertension

A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.

Ultra-Short-Acting β-Adrenergic Receptor Blocking Agents. 2. (Aryloxy)propanolamines Containing Esters on the Aryl Function

Several short-acting β-adrenergic receptor blocking agents have been prepared by incorporating ester functions into the aryl portion of certain (aryloxy)propanolamine systems.In particular, methyl 3-phenyl>propionate hydrochloride (ASL-8052) was found to be a moderately potent, cardioselective compound with a short duration of action when determined in in vivo canine models.